Abstract: There are provided a production method for a therapeutic agent for arthrosis, in which a population including a plurality of mesenchymal stem cells being cultured is imaged to acquire a cell image, the cell image is analyzed to derive density information on the mesenchymal stem cells in the cell image, colonies, which are formed by the mesenchymal stem cells in the population, are detected based on the density information, and the population is sorted based on at least one of an average colony size or a colony forming unit, which is derived from the detected colonies, and provided a therapeutic agent for arthrosis, which is produced by the production method for a therapeutic agent for arthrosis.

Abstract: An object of the present invention is to provide a production method for a synovium-derived mesenchymal stem cell, by which proliferation efficiency is improved so that a sufficient amount of synovium-derived mesenchymal stem cells can be obtained from a synovial tissue, a production method for a cell preparation for joint medical treatment using the production method for a synovium-derived mesenchymal stem cell, synovium-derived mesenchymal stem cell, and a cell preparation for a joint medical treatment. According to the present invention, there is provided a production method for a synovium-derived mesenchymal stem cell, which is a method of producing a synovium-derived mesenchymal stem cell from a synovial tissue, where the production method includes treating the synovial tissue with a mixed enzyme including one or more kinds of collagenases and one or more kinds of neutral proteases for 2 hours or more without causing the synovial tissue to undergo a disinfection step.

Abstract: An object of the present invention is to provide a production method for a synovium-derived mesenchymal stem cell, which makes it possible to obtain a sufficient amount of synovium-derived mesenchymal stem cells from the synovial tissue, a production method for a cell preparation for joint medical treatment using the production method for a synovium-derived mesenchymal stem cell, synovium-derived mesenchymal stem cell, and a cell preparation for a joint medical treatment. According to the present invention, there is provided a production method for a synovium-derived mesenchymal stem cell, which includes treating a synovial tissue with an enzyme for 2 hours or more; and washing a mixture after the enzyme treatment until a residual enzyme concentration in a supernatant is 0.5 ng/mL or less, to obtain a synovium-derived mesenchymal stem cell.

Abstract: The present inventors have clarified that activin has an activity of promoting the proliferation of MSCs and an activity of promoting the regeneration of meniscus or cartilaginous tissue without affecting differentiation multipotency. Further, the present inventors have also found that the use of activin makes it possible to treat and prevent meniscus damage or cartilage disorders, including suppression of degenerative degeneration of cartilage and pain.

Abstract: A joint image unfolding apparatus, a joint image unfolding method, and a non-transitory computer readable recording medium storing a joint image unfolding program are provided to make it possible to check information regarding the entire cartilage in a joint with high accuracy. An image obtaining unit (21) obtains a three-dimensional image of a joint having cartilage. An unfolding unit (23) unfolds the cartilage included in the three-dimensional image with reference to a specific reference axis in the joint to generate an unfolded image.

Abstract: An object of the present invention is to provide a preservative solution for human stem cells, a human stem cell suspension, and a method for preserving human stem cells, which enable preservation of human stem cells at a high survival rate for cells. According to the present invention, a preservative solution for human stem cells is provided. The preservative solution includes at least human serum, in which a volume ratio of human serum with respect to the entire preservative solution is 0.70 or more, and the human stem cells are preserved at a temperature higher than 0° C.

Abstract: A method comprises obtaining a first cell image of a cell by a first observation method, obtaining a second cell image of the cell by a second observation method that is different from the first observation method, and determining the region of the cell based on the first cell image and the second cell image.

Abstract: A method comprises obtaining a first cell image of a cell by a first observation method, obtaining a second cell image of the cell by a second observation method that is different from the first observation method, and determining the region of the cell based on the first cell image and the second cell image.

Abstract: Proliferation of cancer cells is effectively inhibited. Provided is a cancer cell-inhibiting ceramic containing a ?-tricalcium phosphate porous granule with a particle size of 1 to 10 ?m. The ?-tricalcium phosphate porous granule is taken up into cancer cells at an affected area and have an effect of inhibiting proliferation of a cancer tissue. The ?-tricalcium phosphate porous granule with a particle size of 1 to 10 ?m can be used to more effectively inhibit the proliferation of the cancer cells.

Abstract: An object of the present invention is to provide a method for treating defects of articular cartilage or meniscus of a patient using in vivo chondrogenesis of synovium-derived MSCs. The present invention provides a method for treating a disease associated with defects of cartilage or meniscus. In the present invention, the method for treating a disease associated with defects of cartilage or meniscus comprises the following steps: culturing ex vivo autologous synovium-derived mesenchymal stem cells (MSCs); implanting the MSCs such that said cartilage defect site or meniscal defect site is covered by the MSCs; and regenerating cartilage tissue at the cartilage defect site or meniscal defect site in situ by differentiating the MSCs into cartilage cells.

Abstract: The present invention encompasses methods and compositions for enhancing the growth of adult marrow stromal cells.

Abstract: Marrow stromal cells (MSCs) are adult stem cells from bone marrow that can differentiate into multiple non-hematopoietic cell lineages. Colonies of human MSCs were shown to contain both small, rapidly self-renewing stem cells (RS cells) and large, more mature cells (mMSCs). Samples enriched for RS cells had a greater potential for multipotential differentiation than samples enriched for mMSCs. Also, RS cells have a series of surface epitopes and expressed proteins that can be used to differentiate RS cells from mMSCs. The results suggest that it will be important to distinguish the two major sub-populations of MSCs in defining their biology and their potentials for cell and gene therapy.

Abstract: Marrow stromal cells (MSCS) are adult stem cells from bone marrow that can differentiate into multiple non-hematopoietic cell lineages. Colonies of human MSCs were shown to contain both small, rapidly self-renewing stem cells (RS cells) and large, more mature cells (mMSCs). Samples enriched for RS cells had a greater potential for multipotential differentiation than samples enriched for mMSCs. Also, RS cells have a series of surface epitopes and expressed proteins that can be used to differentiate RS cells from mMSCs. The results suggest that it will be important to distinguish the two major sub-populations of MSCs in defining their biology and their potentials for cell and gene therapy.

Abstract: The present invention encompasses methods and compositions for enhancing the growth of adult marrow stromal cells.

Abstract: The present invention includes a method for differentiating marrow stromal cells (MSCs) in vitro. The present invention also includes a method for improving the recovery rate of a mammal afflicted with a neuronal injury. The present invention also includes a method for enhancing the differentiation of marrow stromal cells to hypertrophic chondrocytes.

Abstract: Marrow stromal cells (MSCS) are adult stem cells from bone marrow that can differentiate into multiple non-hematopoietic cell lineages. Colonies of human MSCs were shown to contain both small, rapidly self-renewing stem cells (RS cells) and large, more mature cells (mMSCs). Samples enriched for RS cells had a greater potential for multipotential differentiation than samples enriched for mMSCs. Also, RS cells have a series of surface epitopes and expressed proteins that can be used to differentiate RS cells from mMSCs. The results suggest that it will be important to distinguish the two major sub-populations of MSCs in defining their biology and their potentials for cell and gene therapy.